Mozavaptan
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code | none |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | 137975-06-5 |
PubChem (CID) | 119369 |
IUPHAR/BPS | 2197 |
ChemSpider | 106618 |
UNII | 17OJ42922Y |
ChEMBL | CHEMBL420762 |
Chemical and physical data | |
Formula | C27H29N3O2 |
Molar mass | 427.53 g/mol |
3D model (Jmol) | Interactive image |
| |
| |
(what is this?) (verify) |
Mozavaptan (INN) is a vasopressin receptor antagonist marketed by Otsuka. In Japan, it was approved in October 2006 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH) due to ADH producing tumors.
References
- H. Spreitzer (November 20, 2006). "Neue Wirkstoffe - Conivaptan". Österreichische Apothekerzeitung (in German) (24/2006).
- Prous Science: Molecule of the Month November 2006
This article is issued from Wikipedia - version of the 9/11/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.